Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia

View ORCID ProfileAnton Barchuk, View ORCID ProfileAnna Bulina, View ORCID ProfileMikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, View ORCID ProfileOksana Stanevich, Dmitriy Skougarevskiy, Artemiy Okhotin
doi: https://doi.org/10.1101/2022.01.24.22269714
Anton Barchuk
1Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
5NN Petrov National Research Medical Centre of Oncology, Pesochny, Leningradskaya Ulitsa 68, St. Petersburg, Russia, 197758
6Health Sciences, Faculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, Tampere, Finland, 33520
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anton Barchuk
  • For correspondence: abarchuk{at}eu.spb.ru
Anna Bulina
1Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Bulina
Mikhail Cherkashin
2Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mikhail Cherkashin
Natalia Berezina
2Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatyana Rakova
2Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darya Kuplevatskaya
2Medical Institute named after Berezin Sergey, Esenina Ulitsa 2-3a, St. Petersburg, Russia, 194354
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oksana Stanevich
1Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
4ITMO University, St. Petersburg, Russia, 197101
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oksana Stanevich
Dmitriy Skougarevskiy
1Institute for Interdisciplinary Health Research, European University at St. Petersburg, Shpalernaya Ulitsa 1, St. Petersburg, Russia, 191187
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Artemiy Okhotin
3Tarusa Hospital, Karla Libknekhta Ulitsa 16, Tarusa, Russia, 249100
4ITMO University, St. Petersburg, Russia, 197101
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Studies of mRNA and vector-based vaccines used in different countries report acceptable levels of effectiveness against SARS-CoV-2 infection caused by the Delta variants of SARS-CoV-2. No studies estimated vaccine effectiveness (VE) of Gam-COVID-Vac and other vaccines used in Russia against symptomatic infection with Delta variant. In this population-based case-control study, we aimed to estimate the effectiveness of the Russian COVID-19 vaccines against symptomatic SARS-CoV-2 during the recent outbreak caused by the Delta VOC in October 2021 in St. Petersburg, Russia.

Methods In a population-based case-control study with density sampling of controls, we acquired information on cases and controls from two independent studies conducted in St. Petersburg. Cases were symptomatic patients with confirmed SARS-CoV-2 (using polymerase chain reaction (PCR) test) referred to low-dose computed tomography (LDCT) triage in two outpatient centres between October 6 and 14, 2021 during the Delta variant outbreak. We recruited the controls during the representative survey of the seroprevalence study conducted during the same period in St. Petersburg using random digit dialling. In the primary analysis, we used logistic regression models to estimate the adjusted (age, gender, and history of confirmed COVID-19) VE against symptomatic SARS-CoV-2 resulted in a referral to triage centre for three vaccines used in Russia: Gam-COVID-Vac, EpiVacCorona, and CoviVac.

Findings We included 1,198 cases and 2,747 controls recruited between the 6th and 14th of October in the final analysis. VE was 58% (95% CI: 50–64) for Gam-COVID-Vac (Sputnik V), 50% (95% CI: 30–64) for 1-dose Gam-COVID-Vac (Sputnik V) or Sputnik Light, -40% (95% CI: 191–33) for EpiVacCorona and 38% (95% CI: 0–62) for CoviVac. Without adjustment for the history of confirmed COVID-19 VE for all vaccines was lower, except for one-dose Gam-COVID-Vac (Sputnik Light). The adjusted VE was slightly lower in women — 52% (95% CI: 41–62) than men — 66% (95% CI: 55–74). It was also higher in younger age. However, in the analysis restricted to participants without a history of confirmed COVID-19, the differences in VE by age group were smaller.

Interpretation In contrast to other Russian vaccines, Gam-COVID-Vac is effective against symptomatic SARS-CoV-2 infection caused by Delta VOC. Effectiveness is likely higher than the estimated 58% due to bias arising from high prevalence of the past COVID-19 in St. Petersburg.

Funding Population-based survey in St. Petersburg was funded by Polymetal International, plc.

Competing Interest Statement

Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Other authors have no conflict of interest to declare.

Funding Statement

Polymetal International plc funded the serological study. The main funder had no role in study design, data collection, data analysis, data interpretation, report writing, or decision to submit the publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee of the MIBS approved the VE study on June 21, 2021. The Ethics Committee of the Pavlov First Saint Petersburg State Medical University approved the joint study of COVID-19 VE in St. Petersburg on July 15, 2021. All research was performed following the relevant guidelines and regulations. All participants signed the informed consent upon referral to the LDCT triage. The joint study of COVID-19 vaccine effectiveness in St. Petersburg was registered at ClinicalTrials.gov (NCT04981405, date of registration: August 4, 2021). This publication covers the data collected at the two outpatient centres of the MIBS that contributed to the study data. The Research Planning Board of the European University at St. Petersburg and the Ethics Committee of the Clinic Scandinavia approved the seroprevalence study on May 20, 2020 and May 26, 2020, respectively. Consent was obtained from all participants of the study. The study was registered with the following identifiers: Clinicaltrials.gov (NCT04406038, submitted on May 26, 2020, date of registration: May 28, 2020) and ISRCTN registry (ISRCTN11060415, submitted on May 26, 2020, date of registration: May 28, 2020).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Study data and code is available online.

https://github.com/eusporg/spb_covid_study20

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 24, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
Anton Barchuk, Anna Bulina, Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Oksana Stanevich, Dmitriy Skougarevskiy, Artemiy Okhotin
medRxiv 2022.01.24.22269714; doi: https://doi.org/10.1101/2022.01.24.22269714
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
Anton Barchuk, Anna Bulina, Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Oksana Stanevich, Dmitriy Skougarevskiy, Artemiy Okhotin
medRxiv 2022.01.24.22269714; doi: https://doi.org/10.1101/2022.01.24.22269714

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13384)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5157)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3274)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14636)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (727)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7511)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)